A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10

Psoriasis Clinical Trial

Official title:

A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 Aqueous Hydrogel to Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02322086
• Other study ID #: PH-10-PS-24
• Status: Completed
• Phase: Phase 2
• First received: December 16, 2014
• Last updated: November 8, 2017
• Start date: January 2015
• Est. completion date: June 2017

Study information

• Verified date: November 2017
• Source: Provectus Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter study of subjects with mild to moderate psoriasis. Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites). Biopsies of one target plaque will be collected at baseline (at least 7 days prior to first study treatment on Day 1) and at Days 29 and 64, with a 7-day interval between biopsy at Day 29 and commencement of application of application of active PH-10 on Day 36. Study data from each subject will serve as an internal control (i.e., assessment at baseline and at the end of application of PH-10 vehicle) for assessment of clinical and cellular response to active investigational agent.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 2017
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men or women, age 18 or older.

• Presence of mild to moderate plaque psoriasis on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous areas).

• At least one target plaque having a minimum diameter of 5 cm (2 inches) with uniform mild to moderate plaque psoriasis.

• Fitzpatrick skin type I-VI.

• Written informed consent by the subject or legal guardian.

Exclusion Criteria:

• Female subjects of childbearing potential who are pregnant, attempting to conceive, not using effective contraception, or who are nursing an infant.

• Subjects who have received PH-10.

• Subjects who have received PUVA or systemic antipsoriatic therapy (immunosuppressants, cytostatics, corticosteroids) within 28 days of study initiation (14 days for methotrexate).

• Subjects who have received UVB light therapy within 14 days of study initiation.

• Subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin or Vitamin D analogs) to the study plaque areas within 14 days of study initiation.

• Subjects who have received any approved or investigational biologic drug therapy for psoriasis within 90 days or 5 half-lives of study initiation.

• Subjects who have participated in a clinical research study within 28 days of study initiation.

• Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.

• Subjects with clinical conditions that, in the opinion of the Investigator, may pose a health risk to the subject because of involvement in the study or detrimentally affect regular follow-up of the subject.

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• Topical Rose Bengal, 0.005%
Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).

Locations

Country	Name	City	State
United States	DermResearch Inc.	Austin	Texas
United States	University of North Carolina School of Medicine	Chapel Hill	North Carolina
United States	International Dermatology Research	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Provectus Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the immunologic, structural and hyperproliferative state of the skin in the target plaque and evidence of cellular atypia following PH-10 application		28 days
Secondary	Psoriasis Severity Index (PSI) changes from pre-treatment		28 days
Secondary	Plaque Response changes from Day 1 pre-treatment		28 days
Secondary	Pruritus Self-Assessment score changes from Day 1 pre-treatment		28 days
Secondary	Correlation of PSI changes with observed histopathologic and immunohistopathologic changes in the skin of the target plaque		28 days
Secondary	Incidence of adverse experiences		28 days
Secondary	Incidence of adverse changes in clinical laboratory tests		28 days
Secondary	Incidence of adverse changes in weight or vital signs		28 days
Secondary	Correlation of adverse experiences with observed histopathologic and immunohistopathologic changes in the skin		28 days